Feb. 9 (UPI) -- Novo Nordisk, the maker of the weight loss drug Wegovy, is suing Hims & Hers for selling a cheaper version of the drug, the company announced Monday.
Novo Nordisk claims that Hims & Hers, a telehealth provider, is selling a drug that violates its patent on the semaglutide drug Wegovy. The company is seeking damages and a ban on the so-called copycat.
"The fact is that their medicines are untested and they're putting patients at risk," said John Kuckelman, general counsel for Novo Nordisk.
Hims & Hers version of the weight loss drug was planned to sell for about $49 for the first month of use, about $100 less than Wegovy.
Related
